혈청 유리 경쇄(sFLC) 분석 시장 : 규모, 점유율, 성장률, 산업 분석, 유형별, 용도별, 지역별 인사이트, 예측(2026-2034년)

Growth Factors of serum free light chain (sFLC) assays Market

The global serum free light chain (sFLC) assays market size was valued at USD 266.13 million in 2025 and is projected to grow from USD 288.43 million in 2026 to USD 569.10 million by 2034, exhibiting a CAGR of 8.87% during 2026-2034. North America dominated the market with a 49.63% share in 2025, supported by high disease prevalence, advanced diagnostic infrastructure, and strong presence of leading companies.

Serum free light chain (sFLC) assays are diagnostic tests used to detect, diagnose, and monitor plasma cell disorders such as multiple myeloma, light chain amyloidosis, and related monoclonal gammopathies. These assays measure kappa and lambda free light chains in human serum, offering high sensitivity and improved disease monitoring compared to conventional methods.

MARKET SIZE SNAPSHOT (AS PER REPORT YEAR)

• 2025 Market Size: USD 266.13 million
• 2026 Market Size: USD 288.43 million
• 2034 Forecast Market Size: USD 569.10 million
• CAGR (2026-2034): 8.87%
• North America Market Share (2025): 49.63%

MARKET DRIVERS

Rising Prevalence of Multiple Myeloma

The increasing global burden of multiple myeloma is a key factor driving demand for sFLC assays. According to 2024 estimates by the American Cancer Society, approximately 35,780 new cases of multiple myeloma are expected to be diagnosed in the U.S. Rising risk factors such as aging populations, family history, and radiation exposure further contribute to disease incidence.

Similarly, growing awareness and screening initiatives across countries such as the U.K., Canada, and Australia are increasing diagnostic testing volumes. The high sensitivity of sFLC assays in detecting minimal residual disease and monitoring treatment response supports their widespread adoption across hospital and pathology laboratories.

Technological Advancements in Diagnostic Assays

Advancements in immunoturbidimetric and ELISA-based technologies are enhancing test accuracy and minimizing errors related to antigen excess. Automation in laboratory diagnostics is improving workflow efficiency, while integration with advanced analyzers is expanding testing capacity.

Major players such as Thermo Fisher Scientific Inc., Sebia, and Siemens Healthineers AG are investing in research and product innovation to strengthen their diagnostic portfolios.

MARKET RESTRAINTS

Limitations in Quantification and Standardization

Despite their clinical benefits, sFLC assays face certain technical limitations. Variability in reagents, instruments, and patient kidney function can affect accuracy. Research published in September 2022 indicated that kidney impairment significantly influences free light chain concentrations, potentially leading to inaccurate reference intervals.

Additionally, high costs of advanced assays and limited access in developing countries may restrict broader adoption.

MARKET OPPORTUNITIES

Increasing R&D and Global Expansion

Key industry players are actively pursuing overseas expansion and regulatory approvals to capture emerging market opportunities.

In January 2023, Thermo Fisher Scientific Inc. completed the acquisition of The Binding Site for USD 2.8 billion, strengthening its specialty diagnostics portfolio for multiple myeloma monitoring.

Companies are also increasing R&D investments to integrate artificial intelligence and automation into advanced diagnostic platforms. Expansion into markets such as China, Japan, and Nordic countries is expected to unlock significant growth potential during the forecast period.

MARKET TRENDS

Shift Toward Free Light Chain Testing

Traditional diagnostic techniques such as serum protein electrophoresis (SPEP) and immunofixation electrophoresis (IFE) have limitations in detecting low-level monoclonal proteins. sFLC assays offer superior sensitivity, enabling early disease detection and improved monitoring of treatment response.

Latex turbidometric methods, particularly Freelite assays, continue to dominate laboratory adoption due to automation compatibility and high throughput capabilities.

IMPACT OF COVID-19

The COVID-19 pandemic negatively impacted the market in 2020 due to reduced hospital visits and decline in routine cancer screening. According to The Binding Site's 2020 annual report, revenue declined by 35% during April and May 2020 compared to the previous year.

However, market recovery began in 2021 as diagnostic services resumed and strategic collaborations increased. Post-pandemic emphasis on early detection of chronic diseases further supported market rebound.

SEGMENTATION ANALYSIS

By Technique

The market is segmented into latex nephelometric, latex turbidometric, ELISA, and lateral flow immunoassay.

• The latex turbidometric segment led the market with an 87.20% share in 2026, supported by strong adoption of Freelite assays globally.
• The ELISA segment is expected to grow at a significant CAGR, owing to high specificity and minimized antigen excess errors.

By Indication

• The multiple myeloma segment is projected to dominate with a 77.31% share in 2026, driven by rising prevalence and increasing regulatory approvals.
• The light chain amyloidosis segment is anticipated to grow steadily due to aging populations and collaborative initiatives such as the ASPIRE program launched in October 2023.

By End-User

• Hospital laboratories held the largest share, supported by increasing patient admissions and establishment of specialized cancer centers.
• Clinical & pathology laboratories are expected to grow considerably during 2025-2032 due to improved infrastructure and rising partnerships.

REGIONAL OUTLOOK

North America

North America generated USD 142.81 million in 2026, maintaining market leadership due to product launches and high disease prevalence. The U.S. market is projected to reach USD 134.43 million in 2026.

Europe

Europe remains the second-largest market, supported by strong distribution networks and increasing clinical trials. The U.K. market is projected to reach USD 21.33 million in 2026, while Germany is expected to reach USD 24.04 million in 2026.

Asia Pacific

Asia Pacific is expected to grow significantly during 2025-2032 due to rising awareness and expanding product registrations. Japan is projected to reach USD 12.13 million in 2026, China USD 8.44 million, and India USD 2.95 million.

Rest of the World

Regions such as Latin America and the Middle East are experiencing gradual adoption due to improving healthcare infrastructure and rising awareness programs.

KEY INDUSTRY PLAYERS

Major companies operating in the market include:

• Thermo Fisher Scientific Inc. (U.S.)
• Siemens Healthineers AG (Germany)
• Sebia (France)
• Diazyme Laboratories, Inc. (U.S.)

Strategic initiatives such as FDA approvals, acquisitions, product launches, and facility expansions are strengthening competitive positioning.

CONCLUSION

The global serum free light chain (sFLC) assays market is projected to grow from USD 266.13 million in 2025 to USD 569.10 million by 2034, expanding at a CAGR of 8.87%. Rising prevalence of multiple myeloma, technological advancements in immunoassays, and increasing global expansion initiatives are key growth drivers. Despite challenges related to assay standardization and alternative diagnostic methods, ongoing R&D investments and expanding cancer screening programs are expected to sustain long-term market growth through 2034.

Growth Rate CAGR of 8.87% from 2026-2034

Segmentation By Technique

• Latex Turbidometric
• Latex Nephelometric
• ELISA
• Lateral Flow Immunoassay

By Indication

• Multiple Myeloma
• Light Chain Amyloidosis
• Others

By End-user

• Hospital Laboratories
• Clinical & Pathology Laboratories
• Others

By Region

• North America (By Technique, Indication, End-user, and Country)
  • U.S.
  • Canada
• Europe (By Technique, Indication, End-user, and Country)
  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Technique, Indication, End-user, and Country)
  • Japan
  • China
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Rest of the World (By Technique, Indication, and End-user)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Multiple Myeloma, by Key Countries, 2025
• 4.2. Technological Advancements in Serum Free Light Chain Assay (sFLC)
• 4.3. Key Industry Developments Mergers, Acquisitions & partnerships
• 4.4. Impact of COVID-19 on the Market

5. Global Serum Free Light Chain (sFLC) Assays Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Technique
  • 5.1.1. Latex Turbidometric
  • 5.1.2. Latex Nephelometric
  • 5.1.3. ELISA
  • 5.1.4. Lateral Flow Immunoassay
• 5.2. Market Analysis, Insights and Forecast - By Indication
  • 5.2.1. Multiple Myeloma
  • 5.2.2. Light Chain Amyloidosis
  • 5.2.3. Others
• 5.3. Market Analysis, Insights and Forecast - By End User
  • 5.3.1. Hospital Laboratories
  • 5.3.2. Clinical & Pathology Laboratories
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Rest of the World

6. North America Serum Free Light Chain (sFLC) Assays Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Technique
  • 6.1.1. Latex Turbidometric
  • 6.1.2. Latex Nephelometric
  • 6.1.3. ELISA
  • 6.1.4. Lateral Flow Immunoassay
• 6.2. Market Analysis, Insights and Forecast - By Indication
  • 6.2.1. Multiple Myeloma
  • 6.2.2. Light Chain Amyloidosis
  • 6.2.3. Others
• 6.3. Market Analysis, Insights and Forecast - By End User
  • 6.3.1. Hospital Laboratories
  • 6.3.2. Clinical & Pathology Laboratories
  • 6.3.3. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Serum Free Light Chain (sFLC) Assays Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Technique
  • 7.1.1. Latex Turbidometric
  • 7.1.2. Latex Nephelometric
  • 7.1.3. ELISA
  • 7.1.4. Lateral Flow Immunoassay
• 7.2. Market Analysis, Insights and Forecast - By Indication
  • 7.2.1. Multiple Myeloma
  • 7.2.2. Light Chain Amyloidosis
  • 7.2.3. Others
• 7.3. Market Analysis, Insights and Forecast - By End User
  • 7.3.1. Hospital Laboratories
  • 7.3.2. Clinical & Pathology Laboratories
  • 7.3.3. Others
• 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 7.4.1. U.K.
  • 7.4.2. Germany
  • 7.4.3. France
  • 7.4.4. Spain
  • 7.4.5. Italy
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia Pacific Serum Free Light Chain (sFLC) Assays Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Technique
  • 8.1.1. Latex Turbidometric
  • 8.1.2. Latex Nephelometric
  • 8.1.3. ELISA
  • 8.1.4. Lateral Flow Immunoassay
• 8.2. Market Analysis, Insights and Forecast - By Indication
  • 8.2.1. Multiple Myeloma
  • 8.2.2. Light Chain Amyloidosis
  • 8.2.3. Others
• 8.3. Market Analysis, Insights and Forecast - By End User
  • 8.3.1. Hospital Laboratories
  • 8.3.2. Clinical & Pathology Laboratories
  • 8.3.3. Others
• 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 8.4.1. Japan
  • 8.4.2. China
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Rest of the World Serum Free Light Chain (sFLC) Assays Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Technique
  • 9.1.1. Latex Turbidometric
  • 9.1.2. Latex Nephelometric
  • 9.1.3. ELISA
  • 9.1.4. Lateral Flow Immunoassay
• 9.2. Market Analysis, Insights and Forecast - By Indication
  • 9.2.1. Multiple Myeloma
  • 9.2.2. Light Chain Amyloidosis
  • 9.2.3. Others
• 9.3. Market Analysis, Insights and Forecast - By End User
  • 9.3.1. Hospital Laboratories
  • 9.3.2. Clinical & Pathology Laboratories
  • 9.3.3. Others

10. Competitive Analysis

• 10.1. Global Market Share Analysis (2025)
• 10.2. Company Profiles
  • 10.2.1. Thermo Fisher Scientific Inc.
    • 10.2.1.1. Overview
    • 10.2.1.2. Products
    • 10.2.1.3. SWOT Analysis
    • 10.2.1.4. Recent Developments
    • 10.2.1.5. Strategies
    • 10.2.1.6. Financials (Based on Availability)
  • 10.2.2. Siemens Healthineers AG
    • 10.2.2.1. Overview
    • 10.2.2.2. Products
    • 10.2.2.3. SWOT Analysis
    • 10.2.2.4. Recent Developments
    • 10.2.2.5. Strategies
    • 10.2.2.6. Financials (Based on Availability)
  • 10.2.3. Sebia
    • 10.2.3.1. Overview
    • 10.2.3.2. Products
    • 10.2.3.3. SWOT Analysis
    • 10.2.3.4. Recent Developments
    • 10.2.3.5. Strategies
    • 10.2.3.6. Financials (Based on Availability)
  • 10.2.4. Diazyme Laboratories, Inc.
    • 10.2.4.1. Overview
    • 10.2.4.2. Products
    • 10.2.4.3. SWOT Analysis
    • 10.2.4.4. Recent Developments
    • 10.2.4.5. Strategies
    • 10.2.4.6. Financials (Based on Availability)